Roche welcomes the updated recommendation of the Subject Expert Committee (SEC) on Tecentriq for metastatic Urothelial Cancer (mUC)


The SEC committee of CDSCO in its meeting minutes dated 18.05.2022 recommended that there is no objection for change in indication of Tecentriq in locally advanced or metastatic Urothelial Carcinoma indication, in line with US FDA approvals. 

This decision by the SEC comes as a big hope for Indian patients and healthcare professionals as it enables them to continue having an immunotherapy option to treat/ manage mUC.

About mUC:

Metastatic urothelial carcinoma (mUC) is an advanced form of the most common type of urinary bladder cancer. The treatment is palliative rather than curative, treatment options are limited, and are associated with high toxicity, low response rates, and limited durability. This type of cancer has high mutational complexity with the potential for many neo-antigens and thus is more likely to respond to immunotherapy. 

As per Globocan 2018, it is estimated that there are over half a million new bladder cancer cases and nearly 2 lakh deaths worldwide. In India, there were nearly 19000 new cases and over 10000 deaths, with an incidence rate (per lakh) of 2.4 and 0.7 in males and females respectively as per recent published data.